27489-63-0

Usage

Uses

Used in Pharmaceutical Industry:
TRANS-4-CBZ-AMINOPHENOL is used as a key intermediate for the synthesis of various pharmaceuticals, contributing to the development of new medications and enhancing the production process of existing ones.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, TRANS-4-CBZ-AMINOPHENOL is utilized as a building block, playing a significant role in the creation of diverse organic compounds for research and commercial applications.
Used in Hair Dye and Colorant Production:
TRANS-4-CBZ-AMINOPHENOL is used as a vital component in the formulation of hair dyes and colorants, providing the necessary properties for effective coloration and adherence to hair strands.
Used in Fine Chemicals Manufacturing:
This chemical compound is also employed as a fundamental building block in the production of fine chemicals, which are utilized in a wide range of applications, including fragrances, flavors, and specialty chemicals.

InChI:InChI=1/C14H19NO3/c16-13-8-6-12(7-9-13)15-14(17)18-10-11-4-2-1-3-5-11/h1-5,12-13,16H,6-10H2,(H,15,17)/t12-,13-

Upstream product

• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 501-53-1 benzyl chloroformate 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 27489-62-9 trans-4-aminocyclohexan-1-ol 
• 6850-65-3 p-hydroxycyclohexylamine 
• 7107-58-6 benzyl N-cyclohexylcarbamate 

Downstream Products

• 22348-44-3 trans-4-Methylamino-cyclohexanol 
• 321427-49-0 [4-(benzyloxy-diisopropylamino-phosphanyloxy)-cyclohexyl]-carbamic acid benzyl ester 
• 321427-47-8 C₃₅H₄₃N₂O₇P 
• 29493-38-7 trans-4-carbobenzoxyaminocyclohexyl p-toluenesulfonate 
• 400899-99-2 tert-butyl ((1r,4r)-4-hydroxycyclohexyl)(methyl)carbamate 
• 400898-24-0 [4-(4-bromo-butoxy)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400898-25-1 {4-[4-(allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid tert-butyl ester 
• 279-40-3 7-aza-bicyclo[2.2.1]heptane 
• 321427-51-4 C₅₄H₅₇N₂O₁₄P 
• 105695-23-6 4-(3-Formyl-4-nitro-phenoxy)-N-(4-hydroxy-cyclohexyl)-N-methyl-butyramide 
• 105695-37-2 N-(4-Hydroxy-cyclohexyl)-N-methyl-4-(2-oxo-1,2,3,5-tetrahydro-imidazo[2,1-b]quinazolin-7-yloxy)-butyramide 

Relevant academic research and scientific papers

Structure based drug design and in vitro metabolism study: Discovery of N-(4-methylthiophenyl)-N,2-dimethyl-cyclopenta[d]pyrimidine as a potent microtubule targeting agent

We report a series of tubulin targeting agents, some of which demonstrate potent antiproliferative activities. These analogs were designed to optimize the antiproliferative activity of 1 by varying the heteroatom substituent at the 4′-position, the basicity of the 4-position amino moiety, and conformational restriction. The potential metabolites of the active compounds were also synthesized. Some compounds demonstrated single digit nanomolar IC50 values for antiproliferative effects in MDA-MB-435 melanoma cells. Particularly, the S-methyl analog 3 was more potent than 1 in MDA-MB-435 cells (IC50 = 4.6 nM). Incubation of 3 with human liver microsomes showed that the primary metabolite of the S-methyl moiety of 3 was the methyl sulfinyl group, as in analog 5. This metabolite was equipotent with the lead compound 1 in MDA-MB-435 cells (IC50 = 7.9 nM). Molecular modeling and electrostatic surface area were determined to explain the activities of the analogs. Most of the potent compounds overcome multiple mechanisms of drug resistance and compound 3 emerged as the lead compound for further SAR and preclinical development.

AZOLE-SUBSTITUTED PYRIDINE COMPOUND

The present invention provides a compound represented by formula [I'| shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula -O-CH2CH2-; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.

IRAK INHIBITORS AND USES THEREOF

The present invention provides quinazoline and quinoline compounds, compositions thereof, and methods of using the same. Also disclosed is the activity of such compounds as inhibitors of IRAK enzymes.

FLT3 INHIBITORS AND USES THEREOF

The present invention provides methods of using compounds of formula I: or compositions thereof for the inhibition of FLT3, and the treatment of FLT3-mediated disorders.

Visible-light-triggered release of nitric oxide from N-pyramidal nitrosamines

Although many organic/inorganic compounds that release nitric oxide (NO) upon photoirradiation (phototriggered caged-NOs) have been reported, their photoabsorption wavelengths mostly lie in the UV region, because X - NO bonds (X=heteroatom and metal) generally have rather strong π-bond character. Thus, it is intrinsically difficult to generate organic compounds that release NO under visible light irradiation. Herein, the structures and properties of N-pyramidal nitrosamine derivatives of 7-azabicyclo[2.2.1]heptanes that release NO under visible light irradiation are described. Bathochromic shifts of the absorptions of these nitrosamines, attributed to HOMO (n)-LUMO (π*) transitions associated with the nonplanar structure of the N - NO moiety, enable the molecules to absorb visible light, which results in N - NO bond cleavage. Thus, these compounds are innate organic caged-NOs that are uncaged by visible light. A visible difference: Nitrosamine derivatives of 7-azabicyclo[2.2.1]heptanes undergo N - NO bond cleavage upon exposure to visible light at wavelengths longer than 420a nm, thereby releasing NO. Bathochromic shifts of the absorptions of these nitrosamines are attributed to HOMO (n)-LUMO (π*) transitions associated with the nonplanar structure of the N - NO moiety (see figure). Copyright

Synthesis and solution properties of pH responsive methoxy poly(ethylene glycol)-b-poly(γ-amino-ε-caprolactone)

A series of water-soluble and cationic methoxy poly(ethylene glycol)-b-poly(γ-amino-ε-caprolactone) (mPEG-b-PACL) has been synthesized via ring opening polymerization of γ-(carbamic acid benzyl ester)-ε-caprolactone (γCABεCL) using mPEG as a macroinitiato

Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors

The discovery of new templates and their subsequent elaboration to clinically useful receptor tyrosine kinase (RTK) inhibitors continues to be an important issue. RTKs are a class of enzymes responsible for the activation of different cellular signal transduction cascades. The majority of the known small molecules RTK inhibitors are ATP-competitive and they are multiple targeted inhibitors. We describe here serotonin derivatives as a new class of multiple targeted RTK inhibitors. In contrast to most other RTK inhibitors they act via a non-ATP-competitive (allosteric) mechanism. Furthermore, they are able to inhibit the proliferation of HUVE cells, fibroblasts and two cancer cell lines.

INHIBITORS OF PROTEIN KINASES

The present invention is directed to compounds of formula (I)-(II) and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hy

(Spirocyclylamido)aminothiophene compounds

Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, R1, X and Y are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestin